Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,781 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J, Iwata N, Watari S, Ushio S, Shiromizu S, Takeda T, Hamano H, Kajizono M, Araki M, Nasu Y, Ariyoshi N, Zamami Y. Matsumoto J, et al. Among authors: takeda t. Eur Urol Focus. 2023 Jan;9(1):141-144. doi: 10.1016/j.euf.2022.07.003. Epub 2022 Jul 29. Eur Urol Focus. 2023. PMID: 35915038
Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma.
Matsumoto J, Nishimoto A, Watari S, Ueki H, Shiromizu S, Iwata N, Takeda T, Ushio S, Kajizono M, Fujiyoshi M, Koyama T, Araki M, Wada K, Zamami Y, Nasu Y, Ariyoshi N. Matsumoto J, et al. Among authors: takeda t. Mol Cell Biochem. 2023 Aug;478(8):1779-1790. doi: 10.1007/s11010-022-04637-4. Epub 2022 Dec 26. Mol Cell Biochem. 2023. PMID: 36571650 Free article.
Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.
Namba K, Tomida S, Matsubara T, Takahashi Y, Kurihara E, Ogoshi Y, Yoshioka T, Takeda T, Torigoe H, Sato H, Shien K, Yamamoto H, Soh J, Tsukuda K, Toyooka S. Namba K, et al. Among authors: takeda t. BMC Cancer. 2019 Feb 26;19(1):175. doi: 10.1186/s12885-019-5374-1. BMC Cancer. 2019. PMID: 30808329 Free PMC article.
Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer.
Ochi K, Suzawa K, Tomida S, Shien K, Takano J, Miyauchi S, Takeda T, Miura A, Araki K, Nakata K, Yamamoto H, Okazaki M, Sugimoto S, Shien T, Yamane M, Azuma K, Okamoto Y, Toyooka S. Ochi K, et al. Among authors: takeda t. Biochem Biophys Res Commun. 2020 Aug 27;529(3):760-765. doi: 10.1016/j.bbrc.2020.06.077. Epub 2020 Jul 19. Biochem Biophys Res Commun. 2020. PMID: 32736704 Free article.
3,781 results